Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

EPI-743 in FA Point Mutations

EPI-743 in Friedreich's Ataxia Point Mutations

Ages: 18-65

Location: University of South Florida

Details: The University of South Florida (USF) in Tampa, FL is looking for adults ages 18-65 to complete a trial for EPI-743 in patients with point mutations. This is a Phase 2A Clinical Trial for Edison Pharmaceutical's EPI-743, also known as Vincerinone™, which aims to improve mitochondrial function by reducing oxidative stress. All participants will receive 400mg of EPI-743 three times daily for 3 months. The sponsor of the trial is Edison Pharmaceuticals, Inc. and the study's lead investigator is Theresa Zesiewicz, MD.

To be eligible for participation, genetic confirmation of Friedreich’s Ataxia is required. Additional eligibility details are available at:

If you are interested in participating, please contact the study coordinator below:

University of South Florida - Tampa, FL
Principal Investigator - Dr. Theresa Zesiewicz
Coordinator – Kevin Allison
Telephone: (813) 974-5909


Site Map     Privacy Policy      Service Terms      Contact      Charity Navigator